Patents-Review.com
ClassID:

20379 āŽ˜

A61K31/4462 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Non condensed pyridines; Hydrogenated derivatives thereof; Non condensed piperidines, e.g. piperocaine only substituted in position 3

Recent Application in this class:
#1
20240009191
2024-01-11

METHOD AND COMPOSITION FOR THE TREATMENT OF DISEASE

 #2
20230142739
2023-05-11

PROTEIN-PROTEIN INTERACTION STABILIZERS

 #3
20220354841
2022-11-10

Subcutaneous delivery of polymer conjugates of therapeutic agents

 #4
20220079930
2022-03-17

Therapeutic Cancer Immune Modulation by Treatment with mTOR Inhibitors

 #5
20200261438
2020-08-20

Compounds affecting pigment production and methods for treatment of bacterial diseases

 #6
20200206129
2020-07-02

Formulations for intravenous administration

 #7
20200138804
2020-05-07

METHODS FOR TREATING CANCER

 #8
20200093816
2020-03-26

Subcutaneous delivery of polymer conjugates of therapeutics agents

 #9
20190290638
2019-09-26

Subcutaneous delivery of poly(oxazoline) polymer conjugates

 #10
20190216790
2019-07-18

Methods for Treating Pruritis

 #11
20190112269
2019-04-18

Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-Nā€²-(3-Fluoro-2-methylphenyl)urea

 #12
20180369135
2018-12-27

FORMULATIONS FOR INTRAVENOUS ADMINISTRATION

 #13
20180207145
2018-07-26

PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES

 #14
20180079722
2018-03-22

HYDROBROMIDE SALT OF N-(4-CHLORO-2-HYDROXY-3-((3S)-3-PIPERIDINYLSULFONYL)PHENYL-N'-(3-FLUORO-2-METHYLPHENYL)UREA

 #15
20170202972
2017-07-20

Subcutaneous delivery of polymer conjugates of therapeutic agents

 #16
20170181987
2017-06-29

Inhibition of IL-8 in the treatment of pain and/or bone loss

 #17
20170100385
2017-04-13

PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES

 #18
20160303250
2016-10-20

Subcutaneous delivery of poly(oxazoline) polymer conjugates

 #19
20160264525
2016-09-15

Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N'-(3-fluoro-2-methylphenyl)urea

 #20
20150174112
2015-06-25

COMPOSITIONS FOR TREATING FRAGILE X AND OTHER DISORDERS METHODS OF USE THEREOF, AND SCREENING FOR COMPOUNDS FOR FRAGILE X AND OTHER DISORDERS

 #21
20140288040
2014-09-25

SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION

 #22
20130338118
2013-12-19

Compounds for treatment of heart failure

 #23
20120027723
2012-02-02

TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION

 #24
20110275797
2011-11-10

N-acyl anthranilic acid derivative or salt thereof

 #25
20100178259
2010-07-15

REDUCING FIBROSIS USING MATRIX METALLOPROTEINASE INHIBITORS

 #26
20090069302
2009-03-12

CHEMICAL COMPOUNDS

 #27
20080312279
2008-12-18

Compositions for Treating Fragile X and Other Disorders Methods of Use Thereof, and Screening for Compounds for Fragile X and Other Disorders

 #28
20070232622
2007-10-04

Small molecule toll-like receptor (TLR) antagonists

 #29
20060241188
2006-10-26

Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors

 #30
20060142594
2006-06-29

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

 #31
20050119273
2005-06-02

Small molecule toll-like receptor (TLR) antagonists